Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal duration of oxaliplatin in postoperative XELOX adjuvant chemotherapy for stage II/III gastric cancer
KCT0006098Phase 3Recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, capecitabine in gastric cancer (GC), sponsored by Ministry of Health & Welfare. Started Sep 2021; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0006098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006098.